COMMUNIQUÉS West-GlobeNewswire

Lite Strategy Reports Fiscal 2026 Second Quarter Results
17/02/2026
Second Quarter Performance Driven by Successful Deployment of Treasury Operations; Reflecting Commitment to Strategic Focus on Leveraging Litecoin Holdings Complemented by Disciplined Capital Allocation SAN DIEGO, Feb. [...]
Earth Science Tech, Inc. Announces Initiatives to Advance Public Company Strategy; Expects Approximately $1.4 Million in Annualized Savings and Fiscal 2026 Net Income Growth of More Than 40%, from $3.3 Million to $4.7 Million
17/02/2026
Outlines strategic portfolio actions, governance enhancements and capital discipline plans to support next phase of growth MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “ [...]
Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board
17/02/2026
Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn’s disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17 [...]
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
17/02/2026
CERRITOS, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN) (“Liminatus” or the “Company”) , a pre-clinical stage immuno-oncology company developing next-generation CD47-blockade therapies [...]
Earth Science Tech, Inc. (ETST) Upgrades Audit Capabilities, Engages Semple, Marchal & Cooper, LLP as Independent PCAOB Auditor to Support Continued Expansion
17/02/2026
MIAMI, FL, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company focused on a diversified, vertically integrated health and wellness portfolio, [...]
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin
17/02/2026
HOUSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the Japan Patent Office (JPO) has issued a notice of allowance for Patent [...]
Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites
17/02/2026
Kennewick, WA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering its innovative RadioGel ® Radionuclide Therapy ™ (PRnT ™ ) is preparing to open two new production [...]
ViroMissile Expands Phase I IDOV-ImmuneTM Trial to U.S. Sites Following IND Clearance
17/02/2026
SAN DIEGO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- ViroMissile , Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic Virus) platform, today announced the expansion of its ongoing [...]
Sienna Continues Platform Growth in Ontario and British Columbia
17/02/2026
MARKHAM, Ontario, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (" Sienna " or the " Company ") (TSX: SIA) announced today that it has entered into a purchase agreement to acquire a retirement residence in [...]
Earth Science Tech, Inc. (ETST) Reports Third Fiscal Quarter 2026 Results
17/02/2026
Revenue of $8.4 million, up 14.1% year-over-year Gross profit margin of 76.3%, up 71 bps year-over-year Net income of $910,000, up 341% year-over-year Generated positive cash from operations of $1.2 million fiscal year- [...]
Integra LifeSciences Announces Key Executive Leadership Appointments
17/02/2026
Executive team further strengthened with appointments of Teshtar Elavia to the newly created chief technology officer role, Michael Hutchinson as chief legal officer, and Kerri DiPietro as chief quality officer, [...]
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
17/02/2026
AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage [...]
Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial
17/02/2026
PARAMUS, NJ, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage [...]
STRATA Skin Sciences Highlights Meta-Analysis Confirming Clinical Efficacy of 308 nm Excimer Laser for Plaque Psoriasis
17/02/2026
Growing body of clinical data like February 2026 publication from Georgetown University supports optimized, targeted Excimer laser UVB strategies for inflammatory skin conditions HORSHAM, Pa., Feb. 17, 2026 (GLOBE [...]
Nanox to Showcase Nanox.ARC Live in Europe for First Time and Present New AI Capabilities at ECR 2026
17/02/2026
Live demonstrations of the Nanox.ARC will feature at the ECR booth #425 in Hall X4 Oral presentation by Dr. Nogah Shabshin to present data on potential role of digital tomosynthesis in lung cancer screening Oral [...]
BillionToOne to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
17/02/2026
MENLO PARK, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, [...]
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
17/02/2026
Continued expansion of LYTENAVA™ (bevacizumab gamma) in Europe underway, including commercial launch in Austria in January 2026 Additional European launches expected in 2026 Type A meeting request submitted to the U.S. [...]
Cellectar Biosciences Expands Global Intellectual Property Estate
17/02/2026
Strengthens Protection Around Broad Portfolio of Cancer-Targeting Drug Conjugates and Enabling Technologies Provides Key Coverage Across Europe Ahead of Planned 3Q26 Filing for Conditional Marketing Approval with the [...]
Extendicare Announces February 2026 Dividend of C$0.042 per Share
17/02/2026
MARKHAM, Ontario, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of [...]

Pages